These results suggest that despite their ability to induce lethality of tumor cells with BRCA mutations, the intrinsic STAT3 activating effects of PARPi can reduce PARPi anti-tumor activity and counteract the efficacies of immunotherapies. This evidence concerns the gene STAT3 and neoplasm.